Eiger BioPharmaceuticals to Participate in September Conferences

PALO ALTO, Calif., Aug. 29, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. EIGR, focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor conferences in September:

  • Baird 2019 Global Healthcare Conference at the InterContinental Barclay in New York City.  Eiger will present a corporate update with a live webcast on September 4, 9:05-9:35 PM ET.  Eiger will host one-on-one meetings.
  • CITI 14th Annual Biotech Conference at the Four Seasons Hotel in Boston on September 5.  Eiger will host one-on-one meetings.
  • H.C. Wainwright Global Investment Conference at the Lotte New York Hotel in New York City.  Eiger will present a corporate update with a live webcast on September 10, 3:00-3:25 PM ET.  Eiger will host one-on-one meetings.
  • Ladenburg Thalmann 2019 Healthcare Conference at Sofitel Hotel in New York City.  Eiger will present a corporate update with a live webcast on September 24, 12:00-12:25 PM ET.  Eiger will host one-on-one meetings.

Eiger BioPharmaceuticals (PRNewsFoto/Eiger BioPharmaceuticals, Inc.)

The live webcast of the Baird, H.C. Wainwright, and Ladenburg presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab.  A replay of the webcast will be available approximately one hour following the live event.

About Eiger

Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist. 

The Company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.  The company is also advancing peginterferon lambda, a first-in-class interferon, toward Phase 3 for the treatment of HDV.  Eiger is preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors: Ingrid Choong, PhD

Email: ichoong@eigerbio.com   

Phone: 1-650-619-6115

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-september-conferences-300909355.html

SOURCE Eiger BioPharmaceuticals, Inc.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press ReleasesConference Call Announcements
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!